BRPI1004922A2 - composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama - Google Patents

composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama

Info

Publication number
BRPI1004922A2
BRPI1004922A2 BRPI1004922A BRPI1004922A BRPI1004922A2 BR PI1004922 A2 BRPI1004922 A2 BR PI1004922A2 BR PI1004922 A BRPI1004922 A BR PI1004922A BR PI1004922 A BRPI1004922 A BR PI1004922A BR PI1004922 A2 BRPI1004922 A2 BR PI1004922A2
Authority
BR
Brazil
Prior art keywords
hodgkin
lymphoma
disease
treatment
pharmaceutical composition
Prior art date
Application number
BRPI1004922A
Other languages
English (en)
Portuguese (pt)
Inventor
R Haltiwanger Curtis
D Courvoisier Laurent
Eddleston Mark
E Mckean Robert
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1004922(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BRPI1004922A2 publication Critical patent/BRPI1004922A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI1004922A 2009-01-15 2010-01-14 composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama BRPI1004922A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
BRPI1004922A2 true BRPI1004922A2 (pt) 2019-09-24

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1004922A BRPI1004922A2 (pt) 2009-01-15 2010-01-14 composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama

Country Status (16)

Country Link
US (1) US8076366B2 (https=)
EP (1) EP2387400A1 (https=)
JP (1) JP2012515210A (https=)
KR (1) KR20110110293A (https=)
CN (2) CN102281877B (https=)
AU (2) AU2010204765A1 (https=)
BR (1) BRPI1004922A2 (https=)
CA (1) CA2749101A1 (https=)
EA (1) EA020767B1 (https=)
IL (1) IL213725A0 (https=)
MX (1) MX2011007557A (https=)
NZ (1) NZ594010A (https=)
SG (1) SG172810A1 (https=)
UA (1) UA109109C2 (https=)
WO (1) WO2010083276A1 (https=)
ZA (1) ZA201105099B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2516404A4 (en) * 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US9273010B2 (en) * 2011-06-20 2016-03-01 Hetero Research Foundation Process for bendamustine hydrochloride
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PL2827863T3 (pl) 2012-03-20 2019-07-31 Eagle Pharmaceuticals, Inc. Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9598377B2 (en) 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
US9629538B2 (en) 2013-04-26 2017-04-25 Vital Art And Science, Llc Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (https=)
DE159877C (https=)
DE293808C (https=)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5741523A (en) * 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
DE69929440T2 (de) * 1998-07-09 2006-08-17 Cephalon, Inc. Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2002048142A1 (en) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
CA2431319A1 (en) * 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
KR100679990B1 (ko) * 2001-10-15 2007-02-08 헤모텍 게엠베하 재협착증의 방지를 위한 스텐트의 코팅
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
EP1485720B1 (en) 2002-03-22 2008-03-12 Ludwig Maximilians Universität Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
DE10393059D2 (de) * 2002-05-09 2005-05-04 Hemoteq Gmbh Verbindungen und Verfahren zur hemokompatiblen Beschichtung von Oberflächen
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
CA2516191A1 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine

Also Published As

Publication number Publication date
KR20110110293A (ko) 2011-10-06
MX2011007557A (es) 2011-08-12
AU2016204902A1 (en) 2016-08-04
WO2010083276A1 (en) 2010-07-22
NZ594010A (en) 2013-08-30
UA109109C2 (uk) 2015-07-27
ZA201105099B (en) 2012-03-28
AU2010204765A1 (en) 2011-07-28
US8076366B2 (en) 2011-12-13
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
JP2012515210A (ja) 2012-07-05
US20100210701A1 (en) 2010-08-19
SG172810A1 (en) 2011-08-29
IL213725A0 (en) 2011-07-31
CN103554030A (zh) 2014-02-05
CN102281877B (zh) 2014-07-23
EP2387400A1 (en) 2011-11-23
CA2749101A1 (en) 2010-07-22
CN102281877A (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
CL2009000742A1 (es) Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.
BRPI1004922A2 (pt) composição farmacêutica, forma cristalina da base livre de bendamustina e método de tratamento de leucemia linfocítica crônica, doença de hodgkin, linfoma não-hodgkin, mieloma múltiplo ou câncer da mama
EP2496545A4 (en) SULFOMETHYL SUCCINATE, PROCESS FOR THE PRODUCTION THEREOF AND COMPOSITIONS THEREWITH
EP2186837A4 (en) ABA-TRIBLOCK COPOLYMER AND MANUFACTURING METHOD THEREFOR
EP2415792A4 (en) COPOLYMER OF AN OLEFIN AND A CONJUGATED SERVING AND METHOD OF PREPARING THEREFOR
EP2474539A4 (en) DIEPOXY COMPOUND, PREPARATION METHOD AND COMPOSITION WITH THE DIEXOXY COMPOUND
BRPI0810206A2 (pt) Método de tratar câncer
EP2150409A4 (en) POLYOLEFIN-TARPAULIN COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
IT1399202B1 (it) Metodo per la produzione di manufatti elastomerici funzionalizzati e manufatti cosi' ottenuti
EP2903471A4 (en) ADHESIVE, WASHABLE, ANTIMICROBIAL INSERT FOR SHOES AND METHOD FOR THE MANUFACTURE THEREOF
EP2146787A4 (en) ADAPTABLE GLOVE
EP2666797A4 (en) OLEFIN BLOCK COPOLYMER AND MANUFACTURING METHOD THEREFOR
FR2987838B1 (fr) Polyolefine telechelique, et son procede d'obtention
EP2578607A4 (en) TERMINAL UNSATURATED POLYOLEFIN AND MANUFACTURING METHOD THEREFOR
EP2676965A4 (en) ARYLGLYCOSIDE COMPOUND, MANUFACTURING METHOD AND APPLICATION THEREOF
DE502008000766D1 (de) Blasmaschine mit Garniturteilhalter, sowie Garniturteilhalter
EP2415800A4 (en) HYPER-BRANCHED POLYOXYALKYLENE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
FR2956980B1 (fr) Harnais d'encordement a repartiteur d'efforts, et son procede de fabrication
FI20060682A0 (fi) Karbonitridin valmistusmenetelmä
BRPI0819744A2 (pt) Processo do floco de batata doce
EP2650049A4 (en) HYDROGEN TREATMENT CATALYST AND METHOD FOR THE PRODUCTION THEREOF
EP2660855A4 (en) SEMICONDUCTOR DEVICE AND MANUFACTURING METHOD THEREFOR
EP2159282A4 (en) ROSE-FLAVON AND DELPHINIDINE AND METHOD OF PREPARING THEREOF
EP2113521A4 (en) A-OLEFIN POLYMER AND MANUFACTURING METHOD THEREFOR
EP2289967A4 (en) POLYHYDROXYALKANOATE COPOLYMER AND MANUFACTURING METHOD THEREFOR

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.